Abstract Background and Objective Platelets play a pivotal role in thrombotic events
associated with acute coronary syndrome (ACS), making oral antiplatelet therapy a …

Hydrolases are considered the most wide and diverse class of enzymes. Their chemo-, regio-
, and enantioselectivities have been exploited for many years. Their selective hydrolysis and …

Ticagrelor is a direct acting and reversibly binding P2Y 12 antagonist approved for the
prevention of thromboembolic events. Clinical effects of ticagrelor cannot be simply …

Background: Ticagrelor is a recommended P2Y12 receptor inhibitor after acute coronary
syndrome (ACS). Its superiority has been suggested to rely on pleiotropic effects beyond …

Background: Current guidelines from American College of Cardiology (ACC) recommend
ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed …

Background: The dose and time point for switching from clopidogrel to ticagrelor remain
controversial, especially for Chinese acute coronary syndrome (ACS) patients with …

Antiplatelet Agents | SpringerLink Skip to main content Advertisement SpringerLink Account
Menu Find a journal Publish with us Track your research Search Cart Book cover Hemostasis …

The problem of adverse drug reactions is one of the most socially relevant in all countries.
The position of the general practitioner (GP) who maintains continuous attention observing …

The broad interdisciplinary nature of biocatalysis fosters innovation, as different technical
fields are interconnected and synergized. A way to depict that innovation is by conducting a …

Ticagrelor is a potent P2Y12 inhibitor that is increasingly used in acute coronary syndrome.
Although drug-related intrahepatic hemorrhages have been reported with anticoagulant …